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ABSTRACT
Transdermal drug delivery is a noninvasive delivery method which can have
numerous advantages for patients. It bypasses first-pass metabolism and can produce
a constant and sustained delivery flux when compared to other drug delivery
pathways (i.e. oral and injection). To effectively achieve those requirements,
microemulsion (ME) formulations have been used as the drug delivery vehicles
because they can form spontaneously, are thermodynamically stable and possess high
solubilization capacity for drug compounds. This project optimized the composition
of topical biocompatible ME formulations and evaluated their transdermal
permeation capacity.
In this study, medium chain monoglycerides (MCM) was found can act as the
transdermal permeation enhancer in ME formulations. The transdermal permeation
rate of sodium fluorescein (NaFlu) produced by both MCM alone and MCM
incorporate with surfactant mixture (Tw/Sp) were significantly higher (over 30 and
25-fold, respectively) than that produced by phosphate buffered saline (PBS).
Additionally, increasing concentration of MCM leads to an increasing monophasic
region (AT) from 15.2% to 33.2% of pseudo-ternary phase diagrams. When
incorporated with MCM, it is observed that ethanol (EtOH) largely expanded the AT
of pseudo-ternary phase diagrams to 52.3% and effectively improved the transdermal
delivery rate of ME formulations. The transdermal delivery rate of different
surfactants composed with MCM and EtOH based ME formulations was tested in
vitro through hairless mice skin. Both ME formulation contained surfactant BRIJ
O10 and Tween 80 presented great permeation performance (over 33 and 29-fold,
respectively) when comparing with PBS in delivery of NaFlu. Besides, either
surfactant BRIJ O10, Tween 80 or Kolliphor EL showed great results of gentamicin
permeation performance (over 10, 13 and 14-fold, respectively) than in PBS when
composed with MCM and EtOH based ME formulations. Therefore, ME formulation
contains Tween 80 (ME_T8) was selected to assess the bio-distribution of
gentamicin in vivo. Results showed that the gentamicin can’t go through mouse skin
when dissolved in the PBS treatment. It is found that formulation ME_T8 did
facilitate the transdermal delivery of gentamicin through mouse skin to produce
detectable systemic drug levels. Furthermore, it is observed that the cumulative
i

amounts of gentamicin in the kidney increasing 2.3-fold when double dose
gentamicin was applied in comparison with the single dose ME treatment.
These findings indicate monoglyceride-based MEs can act as transdermal drug
delivery vehicles with tunable skin permeation characteristics.
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1 INTRODUCTION
1.1
1.1.1

Introduction of the skin
Overview

Skin is the largest organ of human body that also provides a series of functions
essential for survival. It accounts for up to 16% of body weight with a total surface
area of 1.8 m2. Skin provides physical protection from environmental challenges
such as micro-organisms, ultraviolet radiation, toxic agents and mechanical insults
but also functions by controlling the inward and outward passage of water,
electrolytes and various substances. Since the out layer cells are continuously shed
and replaced by inner layer cells moving up to the surface, this constant change
contributes to the dynamic state of skin (Bensouilah and Buck, 2007).
1.1.2

The structure of the skin

The skin consists of three main layers (Fig 1.1): the epidermis, the dermis and
subcutaneous tissue. The epidermis and dermis are considered as the key components
of skin. The subcutaneous tissue is a layer of subcutaneous fat below them.

Fig 1.1 Cross-section of skin (James et al., 2016). Three layers compose the skin
structure: the epidermis, the dermis and subcutaneous tissue.
1.1.2.1 The epidermis
The epidermis is the external layer composed of layers of keratinocytes but also
containing melanocytes, Langerhans cells and Merkel cells. It acts as the physical
and chemical barrier between the interior body and exterior environment. There are
1

four separate layers of the epidermis: Horny cell layer (stratum corneum), granular
cell layers (stratum granulosum), squamouse cell layer (stratum spinosum) and basal
cell layer (stratum germinativum). These four layers are formed by the various stages
of keratinocyte maturation (James et al., 2016, Lever and Elder, 2005).
Basal Layer: The basal cell layer is the deepest layer of the epidermis. It lies close to
the dermis and comprises mainly dividing and non-dividing keratinoctytes, which are
attached to the basement membrane by hemidesmosomes. Keratinocytes move from
this deeper layer to the surface and continually divide and differentiate. Below the
basal cell layer are blood vessels in the dermis, which supply nutrients to facilitate
this active growth of fresh skin cells. Basal cell will change their content and shape
as they move away from this nutrient supply (Murphy, 1997).
Squamous Layer: Above the basal layer there is the squamous layer which
comprises irregular shaped cells that are initially formed by reproduction and
maturity of basal cells (Murphy, 1997). These cells are connected by intercellular
bridges and desmosomes. Langerhans cells that possess dendritic and immunological
activity are found mainly in this area (Chu, 2008).
Granular Layer: In the granular cell layer, cells display a flattened appearance, lose
their nuclei and their cytoplasm appears granular. Keratin protein also accumulates in
these cells (Chu, 2008).
Horny Layer: The outermost layer of the epidermis is the stratum corneum and is
the final outcome of keratinocyte maturation. This layer is made up of hexagonalshaped, non-viable cornified cells named corneocytes (Blank, 1953, Monash, 1958).
Corneocytes are arranged in overlapping layers surrounded in stacked lipid bilayers
that fill the extracellular space. This spatial arrangement produces a natural physical
and waterproof character to the surface. Dead cells are continually sheded, from the
skin surface which is balanced by the dividing cells moving up from the basal cell
layer. In this layer, melanin is absorbed into the dividing skin cell to protect skin
from ultraviolet light (Bensouilah and Buck, 2007).
1.1.2.2 The dermis
Below the epidermis is the dermis which ranges in thickness from 0.6 mm on the
eyelids to 3 mm on the soles, back and palms. Two layers comprise the dermis. The
2

thin papillary layer has many ridges builds human beings individual fingerprints and
comprises, thin loosely arranged collagen fibers whilst a thicker reticular layer
extends from the base of the papillary layer to the subcutis tissue. Up to 70% of the
dermis is made of collagen fibers which provide strength and toughness to skin. The
remaining area is made up of elastin fibers, which give skin elasticity and flexibility,
and proteoglycan which provides viscosity and hydration. Immune-competent mast
cells and macrophages are also present within the dermis layer. Dermal vasculature,
lymphatics, nervous cells and fibers, sweat glands, hair roots and small quantities of
striated muscle are contained in the fibrous tissue of dermis and these structures
contribute to for the various functions of the skin (Bensouilah and Buck, 2007).
1.1.2.3 Subcutaneous fat
The thickness of subcutaneous fat varies in different body regions. This fat layer is
located in the deepest region of skin and helps reduce the harmful physical effects
from the environment as well as acting as an energy resource (James et al., 2016).
1.1.3

Skin barrier function

The outmost layer of the epidermis is the stratum corneum which largely responsible
skin barrier function. The stratum corneum was considered to be biologically inert
before the mid-1970’s but in the past 30 years, the complicated biological and
chemical properties of stratum corneum have been revealed.

3

Fig 1.2 The “brick and mortar” pattern of stratum corneum. The corneocyte is
protein-based and hydrophobic lipids are extracellularly sequestered in the stratum
corneum (Prausnitz et al., 2012).
The structure of stratum corneum is commonly described with a ‘brick and mortar’
analogy (Fig 1.2). In this model, the corneocytes can be seen as complex
proteinaceous bricks which are made of keratin fibers within an organized matrix.
Depending on factors such as age, location and exposure to UV, the average
thickness of each corneocyte is 1 micrometre. Generally, about 12 to 16 layers of
corneocytes are contained in the stratum corneum (Prausnitz et al., 2012). Within the
stratum corneum, corneocytes are embedded in a lamellar lipid bilayer enriched in
ceramides, cholesterol, and free fatty acids that are released by epidermal organelles
known as lamellar bodies (Elias and Menon, 1991). This lipid bilayer is considered
as the ‘mortar’ in the brick and mortar model and has an important role maintaining
the barrier property of skin. The hydrophobic layer of ceramide lipids adhering to the
cornified cell envelope impede both the outward and inward movement of water
producing a stable water balance (Prausnitz et al., 2012).
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1.2

Topical Drug Delivery

Topical drug delivery is defined as the application of a drug containing formulation
to the skin. It is used to treat cutaneous disorders or the cutaneous manifestations of a
general disease with the intent of containing the pharmacological or other effect of
the drug to the surface of the skin or within the skin layers.
1.2.1

Advantages and disadvantages

The main advantage of topical delivery is to bypass first pass metabolism.
Additionally, it is convenient and easy to apply and avoids the risks and
inconveniences of systemic delivery methods. Topical delivery can also be a more
efficient vehicle by supplying a consistent and continuous level of drug input that
avoids the large drug fluctuations produced by oral and intravenous delivery methods
(Paudel et al., 2010, Kumar et al., 2011).
However, topical drug delivery may cause skin irritation, contact dermatitis or
allergic reactions due to the drug and/or excipients present in the formulation.
Additionally, the enzymatic activity present in epidermis can modify drug
compounds reducing their activity. Furthermore, many drug compounds permeate the
skin poorly therefore topical drug delivery is mainly used for drug compounds that
require limited plasma concentration (Kumar et al., 2011).
1.2.2

Transdermal drug delivery

Topical drug application is used to produce effects at the site of application and
doesn’t produce high drug concentrations in the blood and other tissues. Transdermal
drug delivery refers to the process where drug compounds penetrate through the
upper layers of skin and into deeper tissue or even to sites away from the application
area. Drugs delivered transdermally can pass into the systemic circulation at a
constant concentration, avoiding hepatic first pass metabolism enabling the
application of lower dosages and the use of drug compounds with short biological
half-life (Gaikwad, 2013).
The primary pathway for the diffusion of drug compounds across skin is transepidermal absorption. The biggest barrier to this process is the stratum corneum. The
most common mechanism for diffusion through the stratum corneum is via the
intercellular lipoid route (Flynn and Stewart, 1988).
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Eccrine and sebaceous glands are appendages that can offer a secondary permeation
pathway known as the trans-follicular or shunt pathway. Since eccrine and sebaceous
glands are present all over the body, these avenues are regarded as shunts which
bypass the stratum corneum. However, these pathways have limitations for
percutaneous absorption. The orifices of these glands are small and make up a
negligible amount of skin surface area. Furthermore, molecules cannot diffuse
inwardly against the glands output since they are profusely active and constantly
being evacuated. The opening of the follicular pore provides a more useful pathway
for percutaneous absorption. The envisioned mechanism of permeation is
partitioning into sebum, followed by diffusion through the sebum to the depths of the
epidermis. Subsequent systemic entry is via the vasculature located in the dermis
(Flynn and Stewart, 1988).
1.2.3

Transdermal drug delivery methods

Several methodologies can be used for transdermal drug delivery. They can be
divided into physical or chemical methodologies (Table 1.1). However, transdermal
delivery strategies may involve combinations of the various methodologies.
Table 1.1 Transdermal drug delivery strategies
Physical methods

Chemical permeation enhancers

Electroporation

Solvents and organic acids

Iontophoresis

Polyols

Microneedles

Surfactants, fatty acids, fatty acids esters,

Needle-free and ballistic injections

Azone and

Sonophoresis

sulfoxides and terpenes

its derivatives, amides,

Photomechanical wave
Magnetophoresis
1.2.3.1 Physical Methods:
Utilizing voltage gradients, electroporation and iontophoresis disrupt the SC to
promote the permeation of large molecules like peptides through intact skin (Weaver
et al., 1999). The local anesthetic compound lidocaine has been successfully
delivered transdermally via iontophoresis (Sugar and Neumann, 1984). Some
intravenous drugs are also available through iontophoresis (Turner et al., 1997).
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However, these techniques require large machines, restricting their clinic availability
(Huzil et al., 2011).
Drugs can be transdermally delivered through the use of microneedles and highpressure needle-free injection. These methods facilitate transdermal drug delivery by
bypassing the skin barrier through direct puncturing or abrasion of the SC (Burkoth
et al., 1999). Additionally, ultrasonic and electromagnetic energy has been used for
transdermal deliver via sonophoresis; and magnetophoresis respectively. Mechanical
energy was utilized as photomechanical wave on the skin (Lee et al., 1999). However,
these approaches are generally used as complementary methods and display limited
transdermal delivery performance (Barry, 2001).
1.2.3.2 Chemical permeation enhancers:
Chemical permeation enhancers that reduce the barrier function of skin can also be
used for transdermal drug delivery. There are 3 main groups of chemical permeation
enhancers that are classified according to their mechanism of action. The 1 st group of
enhancers reduce skin barrier function by extracting the lipid layers of the SC, like
solvents (e.g., ethanol) and organic acids (e.g., salicylic acid). The 2 nd group of
enhancers improve transdermal delivery by increasing the solubility of active
compounds in the skin and include polyol compounds such as propylene glycol. The
3rd group enhancers like terpenes, surfactants, fatty acids, fatty acid esters, Azone
and its derivatives, amides and sulfoxides alter the intercellular lipid. Intercellular
lipid phase fluidity is able to improve and its resistance can be limited after applying
surfactants (Cócera et al., 1999, Shokri et al., 2001, Honeywell-Nguyen and
Bouwstra, 2003).
Chemical penetration enhancers acting within the skin should possess; low toxicity,
low irritability and low allergenicity, rapid enhancement with activity and duration
being both predictable and reproducible, no pharmacological activity within the body
and should work unidirectional (i.e. therapeutic agents should be allowed into the
body whilst preventing the loss of endogenous materials from the body) and should
be cosmetically acceptable with an appropriate skin feel. Furthermore, skin barrier
properties should return both rapidly and fully to normal when the penetration
enhancers are removed (Huzil et al., 2011). Although some chemical enhancers
possess a subset of the above attributes, currently no single enhancer possess all
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these ideal properties. Chemical permeation enhancers were chosen to improve the
topical drug applications in this study.
1.3
1.3.1

Medium chain monoglycerides (MCM) as transdermal drug delivery
enhancers
Structures

MCM are fatty acid monoesters of glycerol. Due to the orientation of that molecule,
two isomeric forms exist (Fig 1.3).

Fig 1.3 The chemical structure of MCM (Moonen and Bas, 2014). OCR is a
saturated or an unsaturated hydrocarbon chain with 6 to 12 carbons in length.
1.3.2

Transdermal permeation enhancers

MCM can be formed by both industrial chemical and biological process. By
diacylglycerol lipase, MCM are biochemically formed through the release of a fatty
acid from diglycerides and can break down by monoglyceride lipase. Either animal
or vegetable can be the commercial source, and may be synthetically made as well.
Mono- and diglycerides are commonly added to food products in small quantities as
emulsifiers and considered as GRAS compounds (Informatics, 1973). Commercial
‘MCM’ were used in the cosmetic production which are mixture of MCM,
diglyceirdes and triglycerides before 1969. Then the distilled monoester (94-96%)
were manufactured for food and cosmetic formulation purpose (Kabara, 1991). The
use of glycerides on medical purpose is already commercially available on US
market. For example, transdermal glyceryl trinitrate patch was used to treat stoke
topically and approved by FDA (Paudel et al., 2010).
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1.3.3

MCM as transdermal permeation enhancers

MCM have enhanced the transdermal permeation rate of numerous drug compounds.
Glyceryl monocaprylate (C8) significantly improved the transdermal delivery rate of
pentazocine compared with other permeation enhancers (i.e. isopropyl myristate
solution alone, carboxylic acids, non-ionic surfactants, l-menthol, alcohols, glycol
and urea) from isopropyl myristate solution system (IPM) (Furuishi et al., 2007). In
this study, two derivatives of glyceryl monocaprylate (glyceryl diglycerides and
glyceryl triglycerides) were proved have no permeation enhancement effect of
pentazocine. It also investigated how fatty chain length derived from MCM affect the
permeation rate of pentazocine (table 1.2). The flux reached the highest when
glyceryl monocaproate (GEFA-C6) was tested, indicating that the suitable carbon
number of glycerol ester of fatty acids is around six. Comparing glyceryl
monocaprylate (GRFA-C8) and glyceryl monocaproate (GRFA-C6), the former is
suitable as a permeation enhancer because of its safety and odorless properties.
Table 1.2 Permeation rate (Flux) of pentazocine with various glycerol ester of fatty
acids (GEFAs) (Furuishi et al., 2007)
Enhancer

Flux (g/cm2/h)

IPM alone

14.4  0.8

GEFA-C2

19.0  3.4

GEFA-C4

37.5  6.4

GEFA-C6

158.2  12.5

GEFA-C8

58.0 11.4

GEFA-C10

52.6  3.3

GEFA-C12

27.2  6.8

GEFA-C18

9.7  3.9

In further research, MCM significantly improved the transdermal delivery flux rate
of hydrophilic drug (progesterone) and hydrophobic drug (adenoine) though porcine
ear skin (Hosmer et al., 2009).
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1.3.4

Antimicrobial properties of MCM

Medium chain fatty acids and their corresponding MCM present a broad spectrum of
antibacterial properties in numerous studies. Early research found that glycerol
monolaurate prohibited the group A, B, F, and G streptococci with 10 to 20 g/mL
concentrations (Schlievert et al., 1992). Glycerol monolaurate has also demonstrated
antimicrobial activity against Staphylococcus aureus and Streptococcus pyogenes
(Schlievert and Peterson, 2012). Furthermore, this study also demonstrated that
glycerol monolaurate has the ability to inhibit Haemophilus influenza and
Staohylococcus aureus in biofilm cultures, suggesting that glycerol monolaurate has
the potential as a broad spectrum topical microbial agent. Monocaprin (10:0) has
displayed rapid antimicrobial activity against Chlamydia trachomatis (Bergsson et
al., 1998) and Candida albicans (Bergsson et al., 2001). Furthermore, monocaprin
has been shown to reduce biofilm biomass on mucosal surface and medical
equipment and devices (Thorgeirsdottir et al., 2006a).
Generally, MCM possess more potent antimicrobial activity than the corresponding
fatty acid towards various Gram-positive species. Additionally, other antimicrobial
compounds have displayed synergy with MCM. Glycerol monolaurate and lauric
acid have displayed synergistic antibacterial/anti-biofilm activity when combined
with the aminoglycoside antibiotics, gentamicin and streptomycin (Hess et al., 2014).
1.4
1.4.1

ME formulations as topical drug delivery vehicles
Formation and structure of MEs

MEs are defined as a single, optically isotropic structured solution of surfactant, oil
and water is called a microemulsion (Danielsson and Lindman, 1981). MEs can be
formed with a wide range of oil-surfactant-water compositions and can be either
water-in-oil (W/O) or oil-in-water (O/W) with a characteristic droplet size of 150 nm
or less (Kreilgaard, 2002). As it is difficult to predict ME formation based on the
complex physical-chemical interactions between components, pseudo-ternary phase
diagrams are commonly used to determine the specified oil-surfactant-water
concentration ranges required for the formation of MEs (Chen et al., 2004, Saint
Ruth et al., 1995, Aboofazeli and Lawrence, 1993, Kale and Allen, 1989, Rushforth
et al., 1986).
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A variety of structures and phases can be formed with an oil, surfactant and water
mixture. Visual inspection can easily recognise many of these structures and phases
from their physical appearance. Emulsions are non-transparent and the water and oil
phases will eventually separate; lamellar structures and cubic phases have increased
viscosity; crystalline phases can be discerned by polarised microscopy. (Kreilgaard,
2002) The interface in the MEs is continuously and spontaneously fluctuating. MEs
are dynamic systems and are significantly affected by the composed components.
Both the physio-chemical properties of the components and the ratio between the
components can affect the structure of ME systems (Lam and Schechter, 1987).
Monophasic ME are of consideration as potential drug delivery vehicle in this study
since they are stable, can be easily prepared and have a high capacity for a wide
range drug solubilisation, including lipophilic and hydrophilic compounds in the one
formulation (Lawrence and Rees, 2000). Depending on the properties of the
components, the structure of a ME, can range from being spherical droplets to coarse
agglomerates (Santos et al., 2008).
1.4.2

ME formulation for topical drug delivery

MEs can satisfy all requirements for liquid drug delivery vehicles including
thermodynamic stability (long shelf-life), easy production (zero interfacial tension
and almost spontaneous formation), low viscosity with Newtonian behavior, and
high solubilization capacity. MEs were chosen as ideal liquid vehicles for drug
delivery since the small droplets have better ability to adhere to membranes and to
transport bioactive molecules in a more controlled fashion. (Shakeel et al., 2008)
MEs can be administered into the body orally, topically on the skin, or nasally, as an
aerosol for direct entry into the lung (Kogan, 2006).
MEs have been studied in the last decades since their great potential in many
applications. Significant efforts have obtained due to MEs’ complicated phase
behavior and fascinating microstructures in ME forming systems (Hellweg, 2002,
Langevin, 1992, Schulman et al., 1959, Strey, 1994, Strey, 1996). In spite of these
benefits, only few drug formulations are commercially available in the market. The
dog shampoo “Allermyl®” produced by Virbac® in USA is a ME based application
for dogs and cats. It is designed to clean and release the irritation condition in pets’
skin (Virbac, 2011). Another ME based formulation “Solvium” containing Ibuprofen
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were commercially used to topical treatment, which was produced by Chefaro
(Akzo) (Verma and Hassan, 2013). However, the function of human skin provides a
primary barrier to transdermal delivery (Kreilgaard, 2002).
1.5

The aim of this study

MCM (C6-12) are known transdermal penetration enhancers that have been used for
the transdermal delivery of a range of compounds (Lopes et al., 2005, Lopes et al.,
2009, Hosmer et al., 2009, Lopes et al., 2007). Furthermore, MCM display broad
spectrum antimicrobial activity against a variety of human pathogens (Isaacs et al.,
1995, Thorgeirsdottir et al., 2006b, Bunkova et al., 2011, Hyldgaard et al., 2012).
This combination of activities displayed by MCM may be useful in the development
of novel antimicrobial formulations for topical use. MEs are stable mixtures of oils,
surfactants and water and are ideal for the development of topical formulations
containing MCM and water-soluble drug compounds. Therefore, the broad aim of
this project was to investigate the use of MCM as a transdermal permeation enhancer
for water soluble compounds in ME formulations. The specific aims were:
1.

To identify suitable surfactant/co-surfactant combinations that enable stable

incorporation of MCM into ME formulations.
2.

To examine the effect of surfactant/co-surfactant combinations on the

transdermal permeation enhancing properties of MCM.
3.

To develop and assess a topical ME formulation for the transdermal delivery

of the topical antibiotic, gentamicin.
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2 METHODS AND MATERIALS
2.1
2.1.1

Materials
Chemicals

Span 80-LQ-(SG) and Crodamol GTCC-LG-(SG) were supplied as a gift by
CRODA, Singapore Pty Ltd. Tween 80-LQ-(SG) and BRIJ-O10-SS-(R13) were
purchased from CRODA Australia. Tween 20, Tween 40 and Tween 60 were
purchased from Sigma-Aldrich (USA). Kolliphor EL was a gift from BASF
Australia. Gentamicin sulfate salt and 1, 2 - Decanediol (C8) were from SIGMA –
ALDRICH. Capmul MCM (C8) (EP) and Captex 300 EP/NF were supplied as a gift
from ABITEC Corporation. Gentamicin [3H(G)] sulfate was purchased from
American Radiolabeled Chemicals, Inc. Fluorescein sodium salt was purchased from
Fluka Analytical Sigma. Monocaprylin (C8) was obtained from NU-CHEK Prep
(USA). Hydrogen peroxide (30%) and ethanol 100% undenatured (Ethyl Alcohol
100%) were supplied by Liem Supply and Chem-Supply. Solvable and Ultima Gold
were purchased from PerkinElmer (USA). All other solvents and reagents were
commercial products of analytical grade and were used without further purification.
Milli-Q water (MilliPore, VIC) was used throughout.
2.1.2

Equipment

The Franz diffusion cells (9mm diameter, 5mL volume) and 6 place stirrers were
manufactured by PermeaGear (USA) and the circulating water bath was
manufactured by HAAKE (USA). Handheld LCR Meter U1733C was manufactured
by Agilent (Australia). POLARstar Omega plate reader and Liquid Scintillation
Analyzer were ordered from BMG LABTECH (Australia) and PerkinElmer (USA),
respectively.
2.1.3

Animals

Mice: C57BL/6J mice aged 8-12 weeks. C57BL-6J mice were sourced from
Australian BioResources, Moss Vale.
2.2

Construction of Pseudo-Ternary Phase Diagram

Pseudo-ternary phase diagrams were prepared according to the procedure described
by (Li et al., 2005). Mixtures of oil and surfactant were prepared in 5 mL flat bottom
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tube in the following ratios: 1: 9, 2: 8, 3: 7, 4: 6, 5: 5, 6: 4, 7: 3, 8: 2 and 9: 1. After
equilibration for 10 min at room temperature, aliquots of the oil/surfactant mixtures
were mixed with varying amounts of Milli-Q water (10% to 90% w/w). After
shaking for 5 min, the solutions were allowed to equilibrate overnight. The solutions
were characterised by visual observation and classified as either: (1) MEs which
appeared as clear or translucent, single phase solutions or (2) unstable emulsions
which appeared as cloudy solutions that phased-separated overtime or after
centrifugation at 14000 x g for 5 min.
A Microsoft Excel spreadsheet named “Tri-plot v1.4.2” was used to prepare the
triangular phase diagrams for particle shape and tri-variate date. Adobe Photoshop
CS6 was used to describe variable phases and specific ME samples. The monophasic
region (AT) was the percentage of ME area in the total phase diagram area. In this
article, the pixel amounts of ME area and total phase diagram area were counted by
Adobe Photoshop CS6, which can be used to calculate the AT.
2.3
2.3.1

Measuring transdermal permeation rate through hairless mice skin
Collection of skin tissue from mice

For transdermal permeation experiments conducted in vitro, murine skin tissue was
collected from animals made available through a tissue sharing arrangement with
different researchers at the University of Wollongong with approval from the
University’s Animal Ethics Committee (AE14/23). Mice that had been sacrificed via
CO2 exposure (within 30 min prior), had their backs shaved using electric hair
clippers. The shaved skin area was then surgically excised, removed of all
subcutaneous fat and tissue before being laid flat in a labelled snap lock bag and
stored at -20 °C.
2.3.2

Mounting full thickness mice skin to Franz diffusion cells

The skin tissue was defrosted at 4 °C for 20 minutes, then allowed to heat to room
temperature for 10 minutes. The skin was cut into small sections that completely
covered the reception chamber (approximately 1.5 cm2). The skin was placed onto
the receptor chamber (epidermal side was up). The donor chamber was then placed
on top of the skin and clamped in position (Fig 2.1). The reception chamber was
filled with 5 mL of degassed phosphate buffered saline (PBS) pH 7.4 ensuring no air
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bubbles were trapped under the skin. A stirrer bar was added to receptor chamber and
the assembled diffusion cell was placed into the 6-place magnetic stirrer. The Franz
cells were connected to a recirculating water bath to maintain the temperature at 35
°C.
2.3.3

Assessing the integrity of full thickness hairless mice skin

The integrity of mouse skin was assessed by measuring the electrical resistance
across the skin when mounted in the Franz cell. 400 μl PBS was added in the donor
chamber and allowed to be equilibrated for 5 minutes. Resistance was measured
using a handheld LCR meter (Agilent U1733C) fitted with platinum wire electrodes,
set at 100 Hz in parallel (PAR) mode. The electrodes were inserted into Franz cell as
shown in Fig 2.1 taking care not to touch the skin. For intact skin, resistance was in
the range of 6 to 15 kΩ/cm2 (Novotny et al., 2009). Skin sections with resistance
below this range were discarded.

Fig 2.1 Location of the electrodes when measuring the resistance across skin
mounted in Franz diffusion cells.
2.3.4

Measuring the transdermal permeation of sodium fluorescein

For formulations containing sodium fluorescein (NaFlu), a 200 µL aliquot was
applied to the donor chamber at NaFlu concentration of 1.2 mg/mL. Aluminium foil
was used to loosely cover the top of the receptor chamber and donor chamber to
prevent excessive evaporation. A 100 μL or 200 μL aliquot of receptor fluid was
collected at specified time points during the course of the experiment (24 h) and was
immediately mixed with an equal volume of 10 mM NaOH. To maintain constant
sink conditions, the receptor chamber fluid was maintained at 5 mL by adding an
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equal volume of degassed PBS to replace the aliquot that was withdrawn. For the
duration of the experiment, the Franz cell apparatus and collected samples were
protected from light. The fluorescence intensity of each sample was measured using
a POLARstar Omega plate reader (BMG LABTECH). Plate reader setting are given
below. The optimal gain setting was set automatically on samples from the last time
point. The amount of NaFlu present in each sample was determined from a standard
curve of NaFlu (0 μg/ml to 20 μg/mL) which was included on each plate. The
standard curve was linear in the range of 0 to 1.3 μg/mL. 100 μl samples were added
in the same plate.
The transdermal flux rate (Js) was the ratio of the change in cumulative drug amount
per mouse skin area against the different of collect time point (ng/cm2/h):
Flux rate =

𝛥𝑚
𝑆 ∙ 𝛥𝑡

𝛥𝑚 = The different of cumulative drug amount (ng)
𝛥𝑡 = The change in diffusion time (h)
𝑆 = The area of mouse skin (0.64 cm2)
The cumulative amount permeated (Q24h) through full thickness mouse skin was the
total amount of drug accumulated in the reception chamber after 24 hours divided by
the mouse skin area (ng/cm2).
𝑇ℎ𝑒 𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑝𝑒𝑟𝑚𝑒𝑎𝑡𝑒𝑑 =

𝑚
𝑆

m = The drug amount collected after 24 hours (ng)
S = The area of mouse skin (0.64 cm2)
Details of the protocol:
Emission: 520

Excitation: 485-12

Orbital Averaging: ON

Diameter: 4 mm

Top optic

Position delay: 0.1

Measurement start time: 0.0

Number of flashes per well: 10

Replicates Number: 2

Unit: nmL
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Start concentration: 2,000,000

Factor: 0.5

Start Volume: 200

Factor: 1

Shaking Model: Orbital

Shaking Frequency: 500 rpm

2.3.5

Measuring the transdermal permeation of gentamicin

For formulations containing tritium labelled gentamicin, 20 µl aliquot was applied to
the donor chamber at gentamicin concentration. Each contains 10 mg/mL gentamicin
that was spiked with 0.5 µCi of tritium labelled gentamicin. Aluminium foil was
used to loosely cover the top of the receptor chamber and donor chamber to prevent
excessive evaporation. A 200 μl aliquot of receptor fluid was collected at specified
time points during the course of the experiment (24 h). To maintain constant sink
conditions, the receptor chamber fluid was maintained at 5 mL by adding an equal
volume of degassed PBS to replace the aliquot that was withdrawn.
After all samples in the receptor chamber were collected, 400 µl PBS was used to
wash the skin while in the donate chamber of Franz cell, repeat this and store the
wash in tubes. Donor chambers and clamps were taken off after the wash. Skin tissue
was removed and placed in glass scintillation vials containing 3mL Solvable. The
vials were incubated in the incubator at 50 °C for 4 hours or more, until the tissue is
completely dissolved. Remain buffer from receptor chamber was removed into a
radioactivity waste bottle. 10 μl original radiolabelled formulation was diluted with
90 μl PBS and filled in glass scintillation vials. 100 μl of sample from the wash
buffer, the skin solution and the receptor chamber were mixed with 5 mL Ultima
Gold scintillation cocktail (PerkinElmer), respectively, adding in each scintillation
vial. All vials were numbered on lids and mixed thoroughly by inversion. Remain
buffer from receptor chamber was removed into a radioactivity waste bottle.
All the bottles were placed in the Liquid Scintillation Analyzer (PerkinElmer Tri-Cab
2810TR) and run protocol (Flag 2: JMC dpm) to measure the level of radioactivity.
The protocol (Flag 2: JMC dpm) has the following parameters:
Assay Type: Direct DPM

Radionuclide Name: Direct DPM 3H-UG

Normalization Std DPM: 259700

Quench Set: 3H-UG Quench

Indicator: tSIE/AEC

External Std Terminator: 0.5 2s%
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Static Controller was selected.
After measurement finish, the value of raw DPM was obtained (recorded in the
DPM1 row). The value of raw DPM times the dilution factor to get the corrected
DPM. The absolute amounts of accumulated gentamicin through the skin area
present in the samples (ng/cm2) was able to be calculated by the following equation:
𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑎𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑑𝑟𝑢𝑔 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝑠𝑘𝑖𝑛 =

𝑚(𝑠𝑡) 𝐷𝑃𝑀(𝑠)
∙
𝑆
𝐷𝑃𝑀(𝑠𝑡)

𝐷𝑃𝑀(𝑠) = The raw DPM of sample times dilution factor (50)
𝐷𝑃𝑀(𝑠𝑡) = The raw DPM of 100% dose sample times dilution factor (4)
𝑚(𝑠𝑡) = The amount of drug applied in the 100% dose sample (200 µg)
𝑆 = The area of mouse skin (0.64 cm2)
2.4

Bio-distribution studies in mice

To permit the topical application of formulations directly to skin, the rear flank
region of mice was shaved using electric animal clippers. This was performed two
days prior to the commencement of the experiment.
Mice were divided into 3 treatment groups of 20 individuals as shown in table 2.1.
Mice were topically treated with either PBS containing 10 mg/mL gentamicin, one
dose of the ME containing 10 mg/mL or 2 identical doses of the ME containing 10
mg/mL (See Table 2.2). All formulations were spiked with 1 µCi of tritium labelled
gentamicin (American Radiochemicals, St. Louis USA). To topically apply the
radiolabeled formulations, each mouse was anaesthetised using isoflurane and 20 µl
of the specified formulation was pipetted onto the shaved area skin. To avoid mice
ingesting the formulation applied to their flanks, animals were fitted with an
Elizabethan collar (Kent Scientific, Torrington, USA) while anaesthetised. After
treatment, mice were caged individually for the duration of the experiment
(maximum 48 hours) to prevent inter-animal grooming. These cages were also free
of nesting material and PVC enrichment tubes for this period.
At specified time points post treatment (Table 2.1), 4 mice from each group were
sacrificed using CO2, dissected and blood/tissues collected for analysis. Blood/tissues
were stored frozen at -20°C until processed. Tissues collected post mortem included
skin (site of application and a distant site) and muscle (underneath the site of skin
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collected), blood and major clearance organs such as spleen, liver, lungs, kidney. To
determine if lymphatic circulation is influencing bio-distribution post topical drug
delivery (King et al., 2003), the major lymph nodes (lumbar, axillary and brachial)
were also collected. To demonstrate mice weren’t ingesting the topically applied
formulations, small intestine tissue was also collected and assessed.
Table 2.1 Mice grouping use for bio-distribution studies.
Time Points (h)

3

6

12

24

48

Total

PBS Group

n=4

n=4

n=4

n=4

n=4

20

ME Group

n=4

n=4

n=4

n=4

n=4

20

MEx2 Group

n=4

n=4

n=4

n=4

n=4

20

Group

Overall Total

60

Table 2.2 Topical formulations used for bio-distribution studies.
Formulation

Ingredients

Concentration

Dose Applied

PBS Group

Phosphate buffered saline

100%

6.67 mg/kg

Gentamicin

10 mg/mL

Capmul MCM C8

10% w/w

Ethanol

10% w/w

Tween 80

20% w/w

Water

60% w/w

Gentamicin

10 mg/mL

Capmul MCM C8

10% w/w

Ethanol

10% w/w

Tween 80

20% w/w

Water

60% w/w

Gentamicin

10 mg/mL

ME Group

MEx2 Group

6.67 mg/kg

13.34 mg/kg

For each organ and blood collected from the mice, 1 mL Solvable (Pekin Elmer) was
added. The mixture was incubated at 50°C overnight. After which taking 100 µl from
the mixture and add 5 mL Ultima Gold scintillation cocktail (PerkinElmer) in the
scintillation vial, 0.2 mL of 30% H2O2 was added. All vials were measured by Liquid
Scintillation Analyzer (PerkinElmer Tri-Cab 2810TR) and run protocol (Flag 2: JMC
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dpm) to measure the level of radioactivity. The tissue uptakes were calculated as the
percentage of the accumulated gentamicin per gram of tissue (mg/g or mg/mL).
2.5

Statistical analysis and software

Original data was initially recorded and calculated in Microsoft Excel. Statistical
analyses and comparison figures were generated by Prism 6. One-way ANOVA (and
nonparametric) was used to analyze in vitro permeation test. Two-way ANOVA was
used to analyze in vivo bio-distribution test.
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3 DEVELOPING ME FORMULATIONS CONTAINING MEDIUM CHAIN
GLYCERIDES FOR TRANSDERMAL DELIVERY
3.1

Introduction

Medium chain (C6~C12) chain fatty acids, mono-, di-, and tri-glycerides have been
used in emulsion formulations as absorption enhancers for a variety of drug
compounds (Constantinides et al., 1994). Furthermore, MCM have also been shown
to act as transdermal permeation enhancers (Cornwell et al., 1998, Furuishi et al.,
2007). Previous research using the biocompatible components; medium chain
triglycerides (Crodamol GTCC), medium chain monoglycerides (Capmul MCM C8),
surfactants polysorbate 80 (Tween 80) and sorbitan mono-oleate (Span 80) and water
indicated that ME can be formed with specific ratios of these substances
(Watnasirichaikul et al., 2000). Recently, a ME formulation from this system was
used to facilitate the transdermal delivery of proteins (Russell-Jones and Himes,
2011, Himes et al., 2011).
3.1.1

Characterization of a biocompatible ME system containing medium
chain glycerides

To investigate the transdermal permeation enhancing properties of these ME
formulations, a representative pseudo-ternary phase diagram of the same system
containing Capmul MCM C8: Crodamol GTCC (1:3, w/w), as the oil phase,
Tween80: Span80) (3:2, w/w, as the surfactant phase and water was constructed and
is shown in Fig 3.1. The ME formulation identified in a previous study
(Watnasirichaikul et al., 2000) and used in the following experiments (76% MCM:
GTCC (1:3) and 14% Tween80: Span80 (3:2), 10% water) is indicated at position A
(Fig 3.1).
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Fig. 3.1 Pseudo-ternary phase diagram for a mixture of medium chain glycerides
(Capmul MCM C8: Crodamol GTCC, 1:3), a mixture of surfactants (Tween 80: Span
80, 3:2) and water. ME formulations were defined as being a single phase that was
visually transparent, stable upon ON incubation at room temperature after vigorous
vortexing (Garti et al., 2000). The ME phase boundary is indicated with grey shading.
Specific formulations assessed for transdermal permeation are indicated with A,
marked by the red point. The monophasic ME region is indicated with AT = 8.8%.
3.1.2

In vitro transdermal delivery skin permeation assay

In a previous study, the formulation ME_A (Fig 3.1 and Table 3.1) effectively
delivered peptides and proteins through the stratum corneum into living epidermal
tissue (Himes et al., 2011). To characterize the potential of this formulation for the
transdermal delivery of small molecules, sodium fluorescein (NaFlu) was used as a
model small compound. Additionally, the influence of individual formulation
components on transdermal flux was also assessed (Table 3.1). All formulations
contained 1.2 mg/mL of NaFlu and transdermal permeation of this compound
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through full thickness mouse skin from the various formulations was determined
using Franz diffusion cells.
Table 3.1 Formulation composition and corresponding transdermal permeation
parameters of NaFlu (transdermal flux rate (J s) and cumulative amount permeated
(Q24h)) through full thickness mouse skin. All formulations contained 1.2 mg/mL
NaFlu.
MCM

GTCC

Surfactant

Water

Js

Q24h

(% w/w)

(% w/w)

(% w/w)

(% w/w)

(ng/cm2/h)

(ng/cm2)

ME_A

19

57

14

10

270±47

3,990±255

MCM*

19

-

-

81

754±185

12,368±1,852

Tw/Sp*

-

-

14

86

11±2

166±27

MCM_TS

19

-

14

67

599±126

10,274±2,130

GTCC_TS

-

57

14

29

15±11

148±46

PBS

-

-

-

-

25±10

475±172

Formulation

* indicates the formulation was a visible emulsion; Abbreviations: Tw/Sp – a
mixture of surfactants (Tween 80: Span 80, 3:2)
The transdermal permeation profile of NaFlu from each of the formulations applied
to full thickness mouse skin is shown in Fig 3.2. From these graphs, the maximum J s
of NaFlu produced by each formulation and the total amount of NaFlu accumulated
in the receptor chamber (Q24h) was determined and is presented in Table 3.1.
Application of NaFlu dissolved in PBS produced a Js of 25 ng/cm2/h indicating that
NaFlu does not readily pass through mouse skin. The J s produced by formulation
ME_A (270 ng/cm2/h) was significantly higher (over 10-fold) when compared to the
Js produced by PBS (p < 0.05). This indicates ME_A can act as a transdermal
permeation enhancer for small compounds.
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Fig 3.2 Cumulative transdermal permeation of NaFlu through mouse skin in vitro
over 24 h. All formulations contained 1.2 mg/mL NaFlu and are described in Table
3.1 except for the control formulation (PBS) which consisted of NaFlu dissolved in
PBS solution. Each point represents the mean ± standard deviation of 3 to 4
biological replicates. (Appendix 7.3, 7.4, 7.5, 7.6, 7.7 and 7.10)
To determine how the individual components in formulation ME_A influenced the
transdermal permeation of NaFlu, formulations containing these individual
components were also examined. The application of NaFlu dissolved in either diluted
surfactant (Tween 80: Span 80 (3:2, w/w)) or GTCC and surfactant mixture
(GTCC_TS) to mouse skin resulted in low Js of 11 ng/cm2/h and 15 ng/cm2/h,
respectively. Taken together, this indicates these components do not affect the
transdermal permeation of NaFlu through mouse skin. By contrast, the J s produced
by formulation MCM_TS (599 ng/cm2/h) and MCM alone (754 ng/cm2/h) was
significantly higher (over 25 and 30-fold, respectively) when compare to the J s
produced by PBS (p<0.05). This indicates MCM can act as transdermal permeation
enhancer for small compounds. Furthermore, as there was no significant difference
between flux rates for MCM_TS and MCM alone (p>0.05), this indicates the
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surfactant blend (Tween 80: Span 80 (3:2, w/w)) does not influence the transdermal
permeation enhancing properties of MCM.
3.2

Influence of surfactant type on the transdermal permeation enhancing
properties of MCM

Surfactants are required to form stable ME formulations that are suitable for topical
applications. Therefore, to determine how different surfactants influence the
transdermal permeation enhancing properties of MCM, several surfactants were
mixed with/without MCM (Table 3.3) and these formulations were assessed for
transdermal permeation using NaFlu (Fig 3.3).
Table 3.2 Formulation composition and corresponding transdermal permeation
parameters of NaFlu (Js and Q24h) through full thickness mouse skin. All
formulations contained 1.2 mg/mL NaFlu.
MCM

GTCC

Surfactant

Water

Js

Q24h

(% w/w)

(% w/w)

(% w/w)

(% w/w)

(ng/cm2/h)

(ng/cm2)

MCM_CO

19

0

14

67

180±122

1,427±523

MCM_BJ

19

0

14

67

991±52

17,850±1336

CO

0

0

14

86

94±46

1,507±879

BJ

0

0

14

86

140±90

1,162±875

25±10

475±172

Formulation

PBS

Abbreviations: CO - Kolliphor EL, BJ - BRIJ O10
The transdermal permeation profile of NaFlu from each of the formulations applied
to full thickness mouse skin is shown in Fig 3.3. From these graphs, the J s produced
and Q24h were determined and are shown in Table 3.3. The J s produced by
application of CO (94 ng/cm2/h) and BJ (140 ng/cm2/h) were higher than the J s
produced by PBS (25 ng/cm2/h) (p<0.05). However, these surfactants had contrasting
effects on the transdermal permeation enhancing properties of MCM. The J s
produced by formulation MCM_BJ (991 ng/cm2/h) was significantly higher when
compared to the J s produced by formulation MCM alone (754 ng/cm2/h), suggesting
a possible synergistic interaction between these compounds. In contrast, the Js
produced by MCM_CO (180 ng/cm2/h) was significantly lower (p<0.05) when
compared to the J s produced by MCM alone, indicating a possible antagonistic
interaction between the MCM and Kolliphor EL. As the Js produced by MCM_BJ
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was significantly (p<0.05) higher than the J s produced by MCM_TS and the J s of
MCM_TS was significantly (p<0.05) higher than the Js produced by MCM_CO, this
suggests the enhancing effect of the different surfactants on the rate of NaFlu
transdermal permeation mediated by MCM was found to be: BRIJ O10 >
Tween80/Span80 (1:3, w/w) > Kolliphor EL.
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MCM_CO

15000
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BRIJ
PBS
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5000

0

0

4

8

12

16

Time post application (h)

20

24

Fig 3.3 Cumulative transdermal permeation of NaFlu through mouse skin in vitro
over 24 hours. All formulations contained 1.2 mg/mL NaFlu and are described in
Table 1.3. Each point represents a mean ± standard deviation of 3 to 4 biological
replicates. (Appendix 7.3, 7.6, 7.8, 7.9, 7.10, 7.11 and 7.12)
The Js chosen from the application of MCM was between time point 9 h and 22 h and
from the application of MCM_BJ was between time point 12 h to 22h, which are
both long time gap. This is because during the in vitro experiments of NaFlu, the
sample collection time points were not unified, therefore Js may different with the
actual flux rate and need to be tested in a smaller time interval in the future
experiment. In the next set of experiments of gentamicin, those collection time points
were consistently chosen.
3.3

The effect of MCM concentration on transdermal permeation

Based on the data presented in Table 3.2, it is evident that the combination of MCM
and the BRIJ O10 surfactant produced the highest transdermal permeation activity.
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To determine how BRIJ O10 can be incorporated into the ME system containing the
MCM: GTCC oil phase, pseudo-ternary phase diagrams were constructed using the
water titration method at ambient temperature (25 °C) and are shown in Fig 3.4.

Fig 3.4 Pseudo-ternary phase diagram for a mixture of (a) medium chain glycerides
(Capmul MCM/Crodamol GTCC, 1: 3, w/w), (b) medium chain glycerides Capmul
MCM/Crodamol GTCC (1: 1) in combination with surfactant (BRIJ O10) and water.
The monophasic ME region is indicated with grey shading with A T(a) = 15.4%; AT(b)
= 33.2%. Specific formulations assessed for transdermal permeation ability are
marked by red points and labelled with B, C, D, E and F. A dilution line (indicated
by dotted line) was used to demonstrate the maximum water ratio when mixed with
certain ratio oil mixture and surfactant mixture.
It is evident that the AT in Fig. 3.4(a) is less than that in Fig. 3.4(b). This suggests
that increasing the ratio of MCM in oil phase from 25% to 50% in the
MCM/GTCC/BRIJ system produces a larger AT.
From the pseudo-ternary phase diagram in Figure 3.4 (b), a dilution line within the
single-phase region at the lowest possible concentration of surfactant was identified.
A selection of formulations from along this dilution line (labelled ME_C, ME_,
MG_D, MG_E and MG_F; see Fig 3.4 and Table 3.3) were used to investigate how
MCM

concentration influences

the transdermal permeation properties

MCM/GTCC based formulations.
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Table 3.3 Formulation composition and corresponding transdermal permeation
parameters of NaFlu (J s and Q24h) through full thickness mouse skin. All
formulations contained 1.2 mg/mL NaFlu.
MCM

GTCC

Surfactanta

Water

Js

Q24h

(% w/w)

(% w/w)

(% w/w)

(% w/w)

(ng/cm2/h)

(ng/cm2)

ME_B

24.5

24.5

21

30

570±284

8,489±1029

ME_C

17.5

17.5

15

50

716±179

7,369±1436

ME_D

14

14

12

60

324±217

5,300±3161

ME_E

10.5

10.5

9

70

254±225

3,119±2289

ME_F

7

7

6

80

1,021±396

10,583±4324

PBS

-

-

-

-

25±10

475±172

Formulation

a

The surfactant used in all formulations was BRIJ O10.
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Fig 3.5 Time course of the in vitro transdermal permeation of NaFlu from
MCM/GTCC/BRIJ based formulations over 24 hours. Each point represents a mean
± standard deviation of 3 to 4 replicates. ME formulations ME_B, ME_C, ME_D,
ME_E and ME_F contained 24.5%, 17.5%, 14%, 10.5% and 7% (w/w) MCM_C8
respectively (Table 3.3). NaFlu was used as model drug with 1.2 mg/mL
concentration applied to full thickness mouse skin. (Appendix 7.3, 7.13, 7.14, 7.15,
7.16 and 7.17)
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The transdermal permeation profile of NaFlu from each of the formulations applied
to full thickness mouse skin is shown in Fig 3.5. From these graphs, the maximum Js
of NaFlu produced by each formulation and the accumulated amount of NaFlu in the
receptor chamber (Q24h) was determined (Table 3.3). Application of NaFlu dissolved
in PBS was used as a negative control group.
All formulations were able to significantly enhance the transdermal permeation of
NaFlu through mouse skin (p<0.05) although the flux rates produced by the different
formulations were variable. Formulation ME_F (7% w/w MCM) produced the
highest Js (1,021 ng/cm2/h) which was over 40-fold greater than the Js produced by
NaFlu in PBS. Formulation ME_E produced the lowest J s (254 ng/cm2/h). The J s
produced by ME_E was the lowest and was significantly lower comparing to the J s
produced by ME_F (p<0.05). While these data demonstrate the ability of all
formulations to enhance the transdermal permeation of NaFlu, there was no
correlation between the MCM concentration and the transdermal flux produced by

Transdermal flux rates of NaFlu (ng/cm2/h)

the formulation (Fig 3.6).

2000
1500
1000
500
0
0.0

3.5

7.0 10.5 14.0 17.5 21.0 24.5 28.0
Concentration of MCM in formulation (% w/w)

Fig. 3.6 The relationship between the concentration of MCM in the ME formulation
and the corresponding Js of NaFlu (ng/cm2/h) through full thickness mouse skin.
Each point represents an individual sample replicate. All formulations contained
NaFlu at 1.2 mg/mL.
29

Linear regression analysis was processed in Prism 6. The correlation trend is
indicated by the blue line and the correlation coefficient is 0.137. (R2 = 0.019, Pvalue = 0.555)
3.4

Characterizing the influence of ethanol as a co-surfactant on the ME
systems containing MCM

In previous studies, the co-surfactants such as a short- or medium-chain alcohols are
used to reduce the interfacial tension of ME formulations. While alcohols may
potentially cause skin irritation and dehydration, ethanol is considered safe for
topical formulations where the contact time on skin is short (Morgan et al., 1998).
Therefore, to characterize the influence of ethanol on MEs systems containing MCM,
pseudo-ternary phase diagrams were constructed using different amounts of Capmul
MCM C8: ethanol (1:1, w/w) as the oil phase, surfactants (either BRIJ O10,
Kolliphor EL, Tween 20 and Tween 80) and water (Fig 3.8). Comparing the A T value
of single phase areas between these systems that utilised different surfactants
indicated there were only slight differences with Kolliphor EL (52.7%) > BRIJ O10
(52.3%) > Tween 80 (50.9%) > Tween 20 (41.2%).
Comparing the AT values of Fig 3.7 (a) to Fig 3.4 (b), it is evident that the
monophasic areas in MCM/EtOH based phase diagrams are larger than that of
MCM/GTCC based phase diagram, indicating the ethanol increased the AT when
incorporated with Capmul MCM and BRIJ O10.
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Fig 3.7 Pseudo-ternary phase diagrams for a mixture of MCM and EtOH (Capmul
MCM: EtOH, 1:1, w/w) and surfactants BRIJ O10 (a), Kolliphor EL (b), Tween 20
(c), Tween 80 (d) in combination with water. The AT is indicated with grey shading
with AT(a) = 52.3%; AT(b) = 52.7%; AT(c) = 41.2%; AT(d) = 50.9%. Specific
formulations ME_BJ, ME_CO, ME_T2 and ME_T8 assessed for transdermal
permeation rate are indicated with G, H, I and J on phase diagrams, marked by red
points.
Formulation ME_BJ (G), ME_CO (H), ME_T2 (I) and ME_T8 (J) (Table 3.4) were
selected by identifying the lowest surfactant concentration present in the ME region
that was common to all four surfactant systems examined. The transdermal
permeation profile of NaFlu from each of the formulations applied to full thickness
mouse skin is shown in Fig 3.8. The maximum Js of NaFlu produced by each
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formulation and the total amount of NaFlu accumulated in the receptor chamber was
determined and is presented in Table 3.4. The J s produced by formulation ME_BJ
was significantly higher (over 33-fold) when compared to the J s produced by PBS
(p<0.05). The Js produced by formulation ME_T8 was significantly higher (over 29fold) when compared to the J s produced by PBS (p<0.05). The J s produced by
formulation ME_CO was significantly higher (over 10-fold) when compared to the J s
produced by PBS (p<0.05). The Js produced by formulation ME_T2 was
significantly higher (over 4-fold) when compared to the J s produced by PBS
(p<0.05). All above indicate that ME_BJ ME_T8, ME_CO and ME_T2 can act as a
transdermal permeation enhancer for small compounds.
Table 3.4 Formulation composition and corresponding transdermal permeation
parameters of NaFlu (J s and Q24h) through full thickness mouse skin. All
formulations contained 1.2 mg/mL NaFlu.
Formulationa

EtOH

Surfactant

(% w/w)

(% w/w)

(% w/w)

ME_BJ

10

10

20

60

846±159

13,523±2,135

ME_CO

10

10

20

60

269±187

4,109±1,974

ME_T2

10

10

20

60

123±28

1,817±303

ME_T8

10

10

20

60

732±169

13,225±1,154

MCM/EtOH

10

10

0

80

-

-

-

-

PBS
a Surfactants

Water

Js

MCM

(% w/w) (ng/cm2/h)

Q24h
(ng/cm2)

2,267±926 33,111±11451
25±10

475±172

used in the following formulations: BRIJ O10 (ME_BJ); Kolliphor EL

(ME_CO); Tween 20 (ME_T2); Tween80 (ME_T8). No surfactant was used in
MCM/EtOH. Abbreviations used; MCM - Monoglycerides, EtOH - ethanol.
There is no significant difference between the J s produced by ME_BJ (846 ng/cm2/h)
and ME_T8 (732 ng/cm2/h) (p > 0.05). Meanwhile, there is no significant difference
between the J s produced by ME_CO (269 ng/cm2/h) and ME_T2 (123 ng/cm2/h) (p >
0.05). However, the J s produced by both application of ME_BJ and ME_T8 were
significantly higher when compared to the J s produced by both application of
ME_CO and ME_T2, respectively (p<0.05). The application of NaFlu dissolved in
MCM/EtOH produced the highest J s of 2267 ng/cm2/h comparing to all other
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formulations (P<0.05) indicating the MCM/EtOH mixture promotes the transdermal
permeation for small compounds.
Comparing the transdermal permeation properties of MCM/EtOH and MCM alone
(Table 3.1), the J s produced by formulation MCM/EtOH (2267 ng/cm2/h) was
significantly higher (3-fold) than the J s produced by MCM (754 ng/cm2/h) (p < 0.05).
Since the concentration of MCM/EtOH (20%) is quite close to the concentration of
MCM (19%), this suggests there may be a possible synergistic interaction between
MCM and ethanol which increases the transdermal permeation performance of
formulations that contain both substances. Besides, the Js produced by ME_BJ was
the highest (846 ng/cm2/h) comparing to other MCM/EtOH based ME formulations.
This result is quite similar to the performance of BRIJ O10 containing formulation in
MCM/GTCC based formulations (Table 3.2).
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Fig 3.8 Cumulative NaFlu transdermal delivery for MCM/EtOH based formulations
within 24 hours. BRIJ O10 (ME_BJ), Kolliphor EL (ME_CO), Tween 20 (ME_T2)
and Tween 80 (ME_T8) were incorporated with MCM/EtOH (1:1, w/w) respectively,
each containing NaFlu 1.2mg/mL. Each point represents means ± standard deviation
of 3 to 4 biological replicates. (Appendix 7.3, 7.18, 7.19, 7.20, 7.21 and 7.22)
Taken together, these data suggest that the combination of MCM/EtOH significantly
enhanced the formulation transdermal delivery property for small compounds.
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Moreover, surfactant BRIJ O10 and Tween80 performed better permeation enhancer
property than other surfactants along the MCM/EtOH based systems.

3.5

Discussion

To initially characterise the ME formulation used by Himes et al. (2011) and RussellJones and Himes (2011) for the transdermal delivery of protein, a pseudo-ternary
phase diagram was constructed using the same components (i.e. a 3:1 mixture of
medium chain triglycerides (Crodamol GTCC) and MCM (Capmul MCM C8), a 3:2
mixture of polysorbate 80 (Tween 80) and sorbitan mono-oleate (Span80) surfactants
and water). Comparing this phase diagram (Fig 3.1) with a similar one constructed
previously by Watnasirichaikul et al. (2000), MEs were formed under similar
conditions (where oil/surfactant ratio is between 10:90 and 90:10 with water ≤ 10%
w/w). The maximum percentage of water solubilized in the system was found to be
10% w/w, which is lower than 14% w/w in the study by Watnasirichaikul et al.
(2000). However, if smaller increments of water were used for the titration, a more
accurate phase diagram would be produced allowing for a better comparison between
the two-phase diagrams.
For transdermal permeation studies, NaFlu was used as a model, small hydrophilic
compound as it can be readily quantified using fluorescence spectroscopy. This
model compound is commonly used in transdermal permeation studies (Santos et al.,
2008, Valenta and Schultz, 2004). In this study, formulation ME_A (Himes et al.
(2011) promoted the transdermal delivery of NaFlu through full thickness mouse
skin at a flux rate of 270 ng/cm2/h, which was over 10-fold higher when compared to
NaFlu in PBS (25 ng/cm2/h). This indicates that formulation ME_A has the potential
to be used as a transdermal permeation enhancing formulation for small compounds.
To further characterise this formulation, individual components of the ME_A
formulation were examined alone or in combination to evaluate how they influenced
the transdermal permeation flux rate of NaFlu. While GTCC and the surfactant blend
had no effect on the transdermal permeation of NaFlu when used alone, MCM
significantly increased (over 30-fold) the Js of NaFlu (754 ng/cm2/h) when compared
to the Js produced by NaFlu in PBS indicating MCM acts as the permeation enhancer
in formulation ME_A. In this study, a core role of the in vitro transdermal
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experiment is to determine the ME formulation with relative high J s value. However,
when GTCC and the surfactant blend were mixed with MCM in the ME_A
formulation, the J s was significantly lower (p < 0.05) when compared to the J s
produced by MCM alone. Taken together, these experiments indicate that presence
of GTCC in the formulation decreased the transdermal permeation enhancing
properties of MCM.
It should be noted that the Js chosen from the application of MCM was between time
point 9 h and 22 h and from the application of MCM_BJ was between time point 12
h to 22h, which are both long time gap (Fig 3.3). This is because during the in vitro
experiments of NaFlu, the sample collection time points were not unified, therefore Js
may different with the actual flux rate and need to be tested in a smaller time interval
in the future experiment. In the next set of experiments of gentamicin, those
collection time points were consistently chosen.
In this study, the influence of different surfactants on the transdermal permeation
enhancing properties of MCM were investigated. The inclusion of surfactants in the
topical formulations can enhance transdermal permeation via partially extracting
extracellular lamellar lipids from the stratum corneum (Albanesi et al., 2005).
Additionally, surfactants may also increase the fluidity of the intercellular lipid phase
permitting increased diffusion of small molecules (Huzil et al., 2011). Furthermore,
as many chemical permeation enhancers act by increasing the partition of active
compounds in the stratum corneum, a titration of drug concentrations should be the
subject of future studies to determine how this influences the transdermal flux rates
for various compounds (Barry, 1983).
The transdermal permeation profiles of surfactant test alone (Tween 80: Span 80 (3:2,
w/w), BRIJ O10 and Kolliphor EL) were all significantly lower (p < 0.05) in
comparison with that produced by ME_A application. In comparison with the
transdermal permeation profile of PBS application (25 ng/cm2/h), the application of
BJ (140 ng/cm2/h) and CO (94 ng/cm2/h) were slightly higher (p < 0.05) while the
application of Tw/Sp (11 ng/cm2/h) was slightly lower (p < 0.05). These results show
that either BRIJ O10, Kolliphor EL or Tw/Sp could only slightly influence the
transdermal permeation rate when applying individually. However, when the
surfactants were individually mixed with MCM and assessed for transdermal
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permeation, the NaFlu J s produced by the MCM_BJ formulation (991 ng/cm2/h) was
significantly higher (p < 0.05) when compared to that produced by MCM alone (754
ng/cm2/h), while the J s of NaFlu produced by the MCM_CO formulation (180
ng/cm2/h) was significantly lower (p < 0.05). The J s of NaFlu produced by MCM_TS
(599 ng/cm2/h) similar to that produced by MCM alone. Taken together, these data
indicate different surfactants can have varying effects on the transdermal permeation
enhancing activity of MCM and suggest BRIJ O10 may act synergistically with
MCM, Kolliphor EL may act antagonistically and the Tween 80: Span 80 (3:2, w/w)
blend has no effect. The different behaviours of BRIJ O10, Tween 80: Span 80 (3:2,
w/w) and Kolliphor EL may be the result of distinct interactions with the stratum
corneum. Savić et al. (2009) assessed the colloidal structures and in vitro permeation
performance of topical vehicles contain two model drugs (diclofenac sodium and
caffeine) incorporated with three different lipophilic excipients (GTCC, decyl oleate
and isopropyl myristate). The results suggested that the colloidal structures of topical
delivery vehicles may affect the diffusion through the vehicles and influence their
permeation performance. Formulations used to produce pseudo-ternary phase
diagrams can be further characterized by measuring their electrical conductivity and
rheological properties (Podlogar et al., 2005, Kreilgaard et al., 2000). Conductivity
can be used to identify inversion points where the formulations transition from oil in
water to water in oil emulsion. Furthermore, viscosity and conductivity are known to
sharply increase when emulsion droplets cluster at the percolation threshold (i.e. in a
bicontinuous ME) (Promod Kumar; Mittal, 1999, Gradzielski and Hoffman, 1999,
Podlogar et al., 2004).
To further evaluate, it is necessary to characterize those vehicles with polarization
micrographs, conductivity measure and rheological test. Now that stable, transdermal
permeation enhancing formulations have been identified in this study, specific
formulations should be examined in more detail in future studies to characterize the
physical properties (such as the size and morphology of particles) of the
formulations. Furthermore, the solubility of various hydrophilic and hydrophobic
compounds should be assessed and a titration of different drug concentrations in
formulations should be assessed to determine how these properties influence
transdermal permeation kinetics.
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As can be seen in the pseudo-ternary phase diagram of the original
MCM/GTCC/Tween 80: Span 80 (3:2, w/w) system used by Himes et al. (2011), the
range of suitable component concentrations that can be utilized for the production of
single phase, stable, biocompatible ME formulations is reflected by the AT zone (see
Fig 3.1). Systems with greater AT zones, as determined in pseudo-ternary phase
diagrams have a larger range of stable ME formulations that can be selected for their
biocompatibility and drug solubilizing properties. Different surfactants and cosurfactants can influence the interfacial forces in emulsions, a selection of
surfactants/co-surfactants were assessed for their effect on ME formation. The nonionic surfactant BRIJ O10 has been used successfully in ME systems previously
(Kogan, 2006), therefore a new pseudo-ternary phase diagram consisting of
MCM/GTCC (1:3, w/w), BRIJ O10 and water was constructed in Fig 3.4 (a). The
use of this surfactant produced a larger AT (26.5%) when compared to the ME_A
which contained the Tween 80: Span 80 (3:2, w/w) surfactant blend (AT=12.5%). In
research conducted by Prajapati et al. (2012), it was determined that ME regions can
be expanded by increasing the concentration of MCM in the oil phase of mixture
systems. Therefore, a mixture system of MCM: GTCC (1:1, w/w), BRIJ O10 and
water was characterized through the construction of a new phase diagram (Fig
3.4(b)) and compared to the MCM/GTCC (1:3, w/w), BRIJ O10 and water system
(Fig 3.4 (a)). Increasing the concentration of MCM in these systems did produce an
increased monophasic area. The alternative of MCM content may influence ME
system converting gel region (bicontinuous structures) into W/O or O/W systems
(Kreilgaard, 2002). Later research concluded that MCM composed with GTCC at 1:1
ratio effectively reduced the gel region, thus ME region was expanded and the
particle size was decreased (Prajapati et al., 2012). This suggested that the MCM act
as the co-surfactant with surfactant BRIJ O10 as it has an intermediate hydrophilelipophile balance (HLB) value. To further validate, the particle size of
MCM/GTCC/BRIJ system should be measured.
A complete dilution line within the ME region was identified in the phase diagram of
the MCM: GTCC (1:1, w/w) /BRIJ system (Fig 3.4 (b)) and specific formulations
along this line were used to evaluate the effect of MCM concentration on transdermal
permeation rate. When these ME formulations were assessed for transdermal
permeation using NaFlu, no correlation (R2 = 0.019) between MCM concentration
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and J s was observed (Fig 3.6). The immiscible water and oil phase composed with
the interfacial surfactant film can form distinct internal structure in the ME regions
(Kreilgaard, 2002). This internal structure is significantly affected by the compounds
formed, and the ratio between those compounds. In the dilution system of present
study, the content change of MCM and other composition may alter the ME
structures between oil-in-water structures, water-in-oil structures or bicontinuous
structures. A variety studies has confirmed that the transdermal drug delivery of
micro-emulsion is dependent not only on the its composition, but also on the internal
structures (Kreilgaard et al., 2000, Podlogar et al., 2005). Therefore, the change of
ME internal structure caused by the composition content alternative would be a
reason that produces irregular J s between each formulation. To further evaluate,
using the conductivity measurement and rheological methods would be help to
characterize the ME phase inversion phenomena (Podlogar et al., 2004).
In ME systems, short chain alcohols such as EtOH can act as a co-surfactant and
further decrease the interfacial tension to produce larger areas of AT (Santos et al.,
2008). Therefore, EtOH was mixed with MCM in the ratio of 1: 1 (w/w) in the oil
phase and pseudo-ternary phase diagrams were generated using water and a selection
of different surfactants. A large AT (52.3%) was obtained in Fig 3.7 (a) comparing to
the AT (33.2%) of Fig 3.4 (b), indicating that EtOH incorporated with MCM/BRIJ
eliminated the gel region then particle size has been reduced and ME region was
expanded (Prajapati et al., 2012). It is suggested that EtOH is acting as co-surfactant
with surfactant BRIJ O10 as it has an intermediate HLB value. The particle size in
this system may be worthwhile to measure in further studies.
EtOH facilitates transdermal drug delivery as a solvent type enhancer (Barry, 1991).
In the study of Morimoto et al. (1993), EtOH (40%) composed with 1-menthol
exhibited

synergistic

transdermal

permeation

enhancement

of

morphine

hydrochloride (2,467 g/cm2) when compared with EtOH applied alone (73 g/cm2).
Significant permeation enhancement effect of ketotifen fumarate was also observed
when EtOH incorporated with isopropyl myristate system (Nakamura et al., 1996). In
this study, MCM/EtOH mixture significantly increased the Js of NaFlu in relative to
MCM alone. Thus, we demonstrated that EtOH enhanced the transdermal permeation
properties of MCM, for the first time. For the future studies, assessing different
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concentrations of MCM and EtOH combinations would facilitate the development of
more effective delivery formulations.
To evaluate the effect of variable surfactants, different surfactants were combined
with MCM-EtOH and corresponding transdermal permeation parameters were
presented (Table 3.4). Permeation data presented the NaFlu Js produced by the
MCM-EtOH combinations was significantly higher when compared to the rest
MCM/EtOH based formulations (p < 0.05). The NaFlu Js produced by ME_T8 (732
ng/cm2/h) similar (p > 0.05) to that produced by ME_BJ (846 ng/cm2/h), which were
significantly higher (p < 0.05) than the NaFlu Js produced by both ME_CO (269
ng/cm2/h) and ME_T2 (123 ng/cm2/h). Additional, the NaFlu Js produced by
ME_CO was significantly higher (p < 0.05) than that produced by MCM_T2. Taken
together, these data present different surfactant can have distinct influences on the
transdermal permeation enhancing activity of MCM-EtOH combinations and suggest
surfactant BRIJ O10, Kolliphor EL, Tween 20 and Tween 80 may act
antagonistically with MCM-EtOH combinations. The different performance of
ME_BJ, ME_CO, ME_T8 and ME_T2 may be the result of distinct interactions with
the stratum corneum. It has been mentioned that colloidal structures of topical
delivery formulations may influence the diffusion through the formulations and
affect their permeation profile (Savić et al., 2009). Thus, it is necessary to further
evaluate those formulations with polarization micrographs, conductivity measure and
rheological test. Furthermore, to observe similar trend exist or not, other drug
compounds would be tested.
As the ME_BJ and ME_T8 formulations were found to be the most potent
transdermal permeation enhancers, these formulations were further investigated for
the transdermal delivery of the topical antibiotic, gentamicin.
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4 DEVELOPMENT OF TOPICAL ME FORMULATIONS CONTAINING
GENTAMICIN
4.1

Introduction

Skin and soft tissue infections (SSTIs) are the most common bacterial infections in
humans and represent a large burden on global healthcare systems. SSTIs can be
superficial, uncomplicated infections (including impetigo, erysipelas and cellulitis)
or may be more severe, complicated infections involving deeper tissues which can
require significant surgical intervention (including infected ulcers, major abscesses
and necrotizing fasciitis). Additionally, recent evidence suggests that bacteria
associated with many SSTIs (such as cutaneous abscesses and chronic wound ulcers)
are present as highly persistent biofilm communities that are notoriously difficult to
treat effectively due to the impermeable nature of these bacterial communities (James
et al., 2008).
Topical treatment of SSTIs represents the most direct approach for the delivery of
antimicrobials to local sites of infection. Traditionally, topical antimicrobials are
formulated as ointments/creams for direct application or are incorporated into wound
dressings allowing controlled release at the wound surface. As traditional topical
formulations display limited skin penetration of active antimicrobial compounds,
topical treatment of SSTIs often produces incomplete bacterial eradication leading to
increased rates of bacterial resistance (Lipsky and Hoey, 2009). Therefore, the
development of more efficient and effective delivery mechanisms of topical
antibiotic therapy for SSTIs is needed.
In a recent study by Hess et al. (2014), gentamicin was shown to act synergistically
with glycerol monolaurate to eliminate detectable viable biofilm bacteria. Similarly,
glycerol monocaprylate has also demonstrated synergistic anti-biofilm activity in
combination with gentamicin against S. aureus biofilms (Proctor, 2015b). Therefore,
this part of the study focused on the development of topical ME formulations
containing MCM C8 and gentamicin.
4.2

Identification of suitable ME systems for gentamicin incorporation

To optimise ME formulations containing gentamicin, solubility testing was
conducted to ensure gentamicin was soluble at suitable concentrations in various ME
systems. Gentamicin solubility was assessed in the MCM: GTCC (1: 1)/BRIJ
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O10/water ME system shown in Fig 3.4. Gentamicin was not soluble at 10mg/mL in
any of the specific formulations (ME_B to ME_F) along the minimum surfactant
dilution line identified in Fig 3.4. Gentamicin was soluble in the MCM: EtOH (1:
1)/Surfactant/water ME systems (Fig 3.7) at 10 mg/mL.
4.3

Transdermal permeation kinetics of gentamicin from ME formulations

Accumulated Gentamicin (ng/cm2)

150000

PBS
ME_BJ
ME_CO
ME_T8

100000

50000

0

0

4
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12

16

20

24

Time post application (h)

Fig 4.1 Cumulative transdermal permeation of gentamicin through mouse skin over
24 h after the application of ME formulation containing gentamicin. Formulations
consisted of ME systems containing MCM/EtOH (1: 1, w/w) and either BRIJ O10
(ME_BJ), Kolliphor EL (ME_CO) and Tween 80 (ME_T8) surfactants which
contained 10 mg/mL gentamicin that was spiked with 0.5 Ci of tritium labeled [3H]
gentamicin. Each point represents means ± standard deviation of 3 to 4 biological
replicates. (Appendix 7.23, 7.24, 7.25 and 7.26)
ME formulations identified to be compatible with gentamicin (ME_BJ, ME_CO and
ME_T8) were characterized for transdermal permeation. The composition of the
formulations is shown in Table 4.1. All formulations contained 10 mg/mL of
gentamicin and were spiked with 0.5 µCi of tritium labeled [3H] gentamicin to enable
monitoring of transdermal permeation through mouse skin mounted in Franz
diffusion cells. The transdermal permeation profile of gentamicin produced by these
formulations is shown in Fig 4.1. From these graphs, the J s and accumulated amount
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of gentamicin in the receptor chamber after 24-hour application (Q24h) were
determined and presented in Table 4.1.
Application of gentamicin dissolved in PBS produced a low Js of 525 ng/cm2/h
indicating that gentamicin does not readily pass through full thickness mouse skin
(Fig 4.1). By comparison to PBS, all ME formulations significantly enhanced the
transdermal permeation of gentamicin through mouse skin (p<0.05). The Js produced
by formulations ME_CO (7,633 ng/cm2/h) and ME_T8 (6,948 ng/cm2/h) were
similar (p>0.05) while the Js produced by formulations ME_T8 (6,948 ng/cm2/h) and
ME_BJ (5,350 ng/cm2/h) were similar (p>0.5). The Js produced by application of
ME_CO was significantly higher (over 1.4-fold) than the J s produced by application
of ME_BJ (p<0.05).
Table 4.1 Permeation parameters of gentamicin (Js and Q24h) through full thickness
mouse skin. All formulations contained 10 mg/mL gentamicin.
MCM

EtOH

Surfactant

Water

Js

Q24h

(% w/w)

(% w/w)

(% w/w)

(% w/w)

(ng/cm2/h)

(ng/cm2)

ME_BJ

10

10

20

60

5,350±251 81,464±10,701

ME_CO

10

10

20

60

7,633±957

ME_T8

10

10

20

60

-

-

-

-

Formulationa

PBS

4.4

95,833±6,506

6,948±1,960 81,378±18,375
525±250

3,575±585

Bio-distribution of gentamicin after topical application of a ME
formulation

Although formulation ME_CO presented higher J s and Q24h values, the
MCM/EtOH/Kolliphor EL system was found to display limited stability when used
to solubilise gentamicin. Therefore, the more stable, ME_T8 gentamicin formulation
which effectively enhanced the transdermal permeation of this compound through
full thickness mouse skin (see Fig 4.1), was further assessed in in vivo studies to
determine the bio-distribution of gentamicin after topical application of the
formulation to mice. In this study, gentamicin was dissolved in the ME formulation
ME_T8 (Table 3.4), at 10 mg/mL gentamicin which was spiked with 0.5 µCi of
tritium labeled [3H] gentamicin and topically applied on the shaved dorsal skin of
mice. For the single dose (ME), the formulation was applied as a 10 µl aliquot on the
right side of the dorsal region while the double dose (MEx2) was applied as two
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separated 10 µl aliquots, one on each dorsal side. The negative control formulation
consisted of 10 mg/mL gentamicin dissolved in PBS which was spiked with 0.5 µCi
of tritium labelled [3H] gentamicin that was topically applied on the right side of the
shaved dorsal skin of mice. The gentamicin amount in the mice tissue skin, muscle
(underneath the site of skin collected), blood, small intestine, major lymph nodes
(lumbar, axillary and brachial) and major clearance organs such as kidney, liver,
spleen, lungs, and the wash buffer were measured.
The results of wash buffer, skin, blood and kidney are showing below, the rest results
are presented in the appendix (Appendix 7.27, 7.28, 7.29, 7.30, 7.31 and 7.32).
In Fig 4.2 (a), at all time points except 3 h, the amount of gentamicin stay in the wash
buffer was significantly higher after PBS treatment when compared to both ME
treatment and MEx2 treatment (indicated with **, p < 0.05) while at 3 h that was
significantly higher after PBS treatment comparing to the ME treatment (indicated
with *, p < 0.05). At time 6h and 24 h, the amount of gentamicin accumulated in the
MEx2 treatment was significantly higher than that accumulated in the ME treatment
(indicated with ***, p < 0.05).
In Fig 4.2 (a), the amount of gentamicin remains in the wash buffer after PBS
treatment wasn’t significantly changed during 48 h (p>0.05) and it is significantly
higher comparing to that of ME treatment at all time point (p<0.05). Those results
suggested that the gentamicin of PBS treatment didn’t transdermal delivered into
skin. It is evidence that the decrease trend can be observed in the wash buffer of
MEx2 treatment, indicating the gentamicin was transdermal delivered into the skin.
Similar trend should be observed in the ME treatment as well. Since the amount of
gentamicin in the wash buffer after ME treatment was low and the its SEMs are
relevant big, it didn’t show significant decrease trend in the static analysis.
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Fig 4.2 The amount of gentamicin present in the skin buffer (a) and the amount of
gentamicin accumulated in the skin tissue at the site of topical application (b) over 48
hours post application. All formulations contained 10 mg/mL gentamicin that was
spiked with 0.5 µCi of tritium labelled gentamicin and are described in Table 3.4.
Each point represents a mean ± standard error of the mean (SEM) of 3 to 4 biological
replicates.
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In Fig 4.2 (b), at 3 h the amount of gentamicin in the skin was significantly lower
after ME treatment when compared to the PBS treatment (indicated with *, p < 0.05).
At 48 h, the amounts of gentamicin in the skin were significantly lower after the
application of both ME and MEx2 when compared to the application of PBS
treatment (indicated with **, p < 0.05).
In Fig 4.2 (b), the amount of gentamicin accumulated in the skin after PBS treatment
wasn’t significantly changed during 48 h (p>0.05). However, it is as high as the
MEx2 treatment at the first 24 hours (p>0.05). If the gentamicin of PBS treatment
didn’t penetrate through the skin, one possible reason here would be the gentamicin
precipitation was hard to washed off, it adhered on the skin until the skin was
dissolved in the Solvable and measured. In comparison, the gentamicin amount
accumulated in the skin of MEx2 treatment presented a decrease trend between 3 h
and 12 h (p<0.05), suggesting the gentamicin of MEx2 treatment was transdermal
delivered through the skin. Similar trend supposed to be observed in the ME
treatment as well as the MEx2 treatment. However, since its SEMs were big and
amounts of gentamicin accumulated were low, it didn’t show such a trend in the
static analysis.
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Gentamicin accumulated in the blood (ug/ml)
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Fig 4.3 The amount of gentamicin accumulated in the blood (a) and the kidney (b)
over 48 hours post application. All formulations contained 10 mg/mL gentamicin
that was spiked with 0.5 µCi of tritium labelled gentamicin and are described in
Table 3.4. Each point represents a mean ± standard error of the mean (SEM) of 3 to 4
biological replicates.
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In Fig 4.2 (a), at 24 h and 48 h, the amount of gentamicin accumulated in the blood
was significantly lower after ME treatment and MEx2 treatment (indicated with *, p
< 0.05) when compared with that after PBS treatment. At 3 h and 24 h, the amount of
gentamicin accumulated in blood was significantly higher after MEx2 treatment
comparing to the ME treatment (indicated with **, p < 0.05).
In Fig 4.3 (a), the amount of gentamicin accumulated in the blood was significantly
higher when compared with that of ME treatment at 3 h, proving that the gentamicin
was transdermal delivered into the blood after MEx2 treatment. There is a dramatic
decrease trend (p<0.05) for gentamicin amount accumulated in the blood of MEx2
treatment between 3 h and 12 h, indicating the gentamicin was take part in to the
systemic circle after MEx2 treatment. There is no significant difference (p>0.05) of
gentamicin amount accumulated in blood after both PBS and ME treatment over 24
h.
In Fig 4.2 (b), the gentamicin accumulated in the kidney after MEx2 treatment was
significantly higher than that in both ME and PBS treatment at all time points (p <
0.05). At 6 h, the gentamicin amount accumulated in the kidney of MEx2 treatment
was significantly higher than that in the MEx2 treatment (indicated with *, p < 0.05).
In Fig 4.3 (b) the gentamicin amount accumulated in the kidney after both ME and
MEx2 treatment were significantly higher than that after PBS treatment. Taken
together, above results suggested the amount of gentamicin was transdermal
delivered into the blood and accumulated in the kidney via the systemic circle after
ME and MEx2 treatment. The reason that no significant different was observed of
gentamicin amount in the blood after ME treatment over 24 h may because it’s low
amount of gentamicin and relative high SEM of ME treatment. However, since there
is significantly lower rate of gentamicin accumulated in the kidney after PBS
treatment comparing with that after ME and MEx2 treatment, suggesting that the
gentamicin didn’t transdermal delivered through the skin and take part into the
systemic circle. It is also noticed that the gentamicin amount accumulated in the
kidney demonstrated an increase trend between 3 h and 6 h after ME treatment when
compared with the decrease trend observed in the blood between 3 h and 6 h,
suggesting that the gentamicin was accumulating in the kidney via the blood during
this period.
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4.5

Discussion

Topical gentamicin preparations are commercially available and are used to treat
minor skin infections (such as impetigo, folliculitis) or infections associated with
other skin conditions (such as eczema, psoriasis, minor burns/cut/wound) (Zanca,
1969). Topical gentamicin formulations are currently available as an ointment
(Binenbaum et al., 2010), spray pack solution (Osawa et al., 2016) or a cream
(AlShwaimi et al., 2016). However, previous study observed that the transdermal
delivery of gentamicin from water-miscible bases was greater and faster than from
ointment bases (Stone et al., 1968). Moreover, several former experiments proved
that gel and ointment based topical formulations performed lower value than W/O
emulsions or O/W emulsions in terms of transdermal drug delivery (Gomes et al.,
2004, Fini et al., 2008). These researches suggest that ME could be an interesting
alternative to improve topical delivery of gentamicin. With recent studies
demonstrating synergistic, anti-biofilm activity between MCM and gentamicin, ME
formulations containing MCM and gentamicin were developed and characterised
(Proctor, 2015a, Hess et al., 2014).
Gentamicin was readily soluble in the MCM/EtOH based formulations and three
gentamicin containing formulations (ME_BJ, ME_CO and ME_T8) were assessed
for transdermal delivery (Table 4.1). The gentamicin J s produced by ME_BJ (5,350
ng/cm2/h), ME_CO (7,633 ng/cm2/h) and ME_T8 (6,948 ng/cm2/h) were
significantly higher when compared with that produced by PBS (525 ng/cm2/h). The
gentamicin J s produced by ME_BJ reaching statistical difference in comparison with
that produced by ME_CO. These data indicate that different surfactants can have
different influence on the transdermal permeation enhancing activity of MCM-EtOH
based formulations and suggest ME_BJ, ME_CO and ME_T8 has the potential to
effectively transdermal deliver gentamicin. It is suggested that the colloidal
structures of topical permeation formulations may affect the difference through the
formulation and alter their permeation ability. Furthermore, it is observed that the
performance of gentamicin J s was superior to the performance of NaFlu J s of
formulation ME_CO. Savić et al. (2009) concluded that permeation performance of
two different model drugs may principally affected by the vehicle/solute interaction.
This suggests the transdermal permeation of small compounds can be influenced by
specific interactions with surfactants present in ME formulations (Karande et al.,
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2007, Karande et al., 2004). To investigate, the nature of drug compounds such as
partition coefficient within the formulation and its effect to permeation profile would
be promising to verify in future studies.
Tween 80 is widely used in a variety of drug formulation vehicles and as formulation
ME_T8 produced high transdermal flux for gentamicin ex vivo, this formulation was
assessed for in vivo transdermal delivery using mice (Hosmer et al., 2009,
Watnasirichaikul et al., 2002, Constantinides et al., 1994).
In the bio-distribution experiment performed, mice were topically treated with either
PBS containing 10 mg/mL gentamicin, one dose of the ME containing 10 mg/mL or
two identical doses of the ME containing 10 mg/mL. At each time point, the topical
application site was washed to assess how much of the gentamicin in formulation
remained on the surface of the skin. The amount of gentamicin present in the skin
wash buffer from mice treated with PBS was high and remained relatively constant
over the 48 hours post treatment. The amount of gentamicin present in the skin wash
buffer from mice treated with the ME formulations was consistently lower when
compared to the PBS treated group and was also seen to decline overtime. Taken
together, this suggests that when mice were topically treated with PBS, high
quantities of gentamicin remained on the skin surface and when treated with ME,
gentamicin permeated through the skin more readily.
The profile of gentamicin accumulation in the skin after ME treatment suggests
gentamicin rapidly permeated into deeper skin tissue. After this rapid accumulation
post ME treatment, the concentration of gentamicin was then seen to slowly decline
over time suggesting gentamicin could be spreading systemically. This is further
supported by the gentamicin accumulation profile in kidney whereby after the ME
treatment, gentamicin concentration increases in the first 12 h post application and
then declines over the next 36 hours.
The high amount of gentamicin seen in PBS treated skin may be the result of
gentamicin penetration into skin or inefficient removal of gentamicin from skin
surface by the wash method used. This could be investigated further by using
stronger wash buffers (e.g. those containing higher concentrations of detergent or
ethanol). The penetration of gentamicin into skin layers could be assessed more
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accurately via strip taping striping which has been used to determine the depth and
lateral spread of compounds through skin tissue. (Hahn et al., 2010, Gee et al., 2012).
In the present study, mice treated with ME formulations were shown to accumulate
gentamicin in the kidney. Those treated with PBS formulations did not. This
indicates ME formulations were facilitating transdermal permeation of gentamicin
producing systemic delivery.

This effect was found to be dose dependent as

indicated by those mice in the MEx2 treatment group accumulating 2.3-fold more
gentamicin in the kidney when compared to the single ME treatment at 6 h post
application. In addition, the kidney concentration of gentamicin of MEx2 treatment
reach the highest at 6 h while that of ME treatment reach the highest at 12 h. This
suggests that the MEx2 treatment produces faster transdermal permeation when
compared to the ME treatment. While the majority of drug compounds are excreted
from the body via the kidney, gentamicin is known to cause nephrotoxicity as it
binds to phospholipids within the membrane of the proximal tubule cell specific in
the kidney (Smith et al., 1980). While this may be a potential problem for the topical
gentamicin formulation produced in this project, the data presented in this thesis does
indicate that ME formulations containing the transdermal permeation enhancer,
monocaprylate, can facilitate systemic drug delivery after topical application.
However, producing high systemic drug concentrations post topical application may
have unwanted side effects if the compounds have known systemic toxicity
properties Therefore, in future studies, it will be necessary to optimize the ME
formulation to get good penetration through the skin but reduced systemic dose. The
Js generated in this study would be optimized to produce better localized drug
concentrations versus systemic concentrations (i.e. different drug concentration
elaboration and dosing regimens, systemic concentration). Moreover, based on the
equivalent surface area dosage conversion factors between animal and human
(Rockville, 2005), the gentamicin dose applied in this study (6.67 and 13.34 mg/kg)
would be optimized to use in the next set of in vivo experiments. Last but not least,
the pharmacokinetics should be evaluated in vivo in the future study. For example,
the process of antibiotics release from the ME based formulations and the removal of
gentamicin

from

the

body

should
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be

designed

and

evaluated.

5 CONCLUSIONS
ME formulations have great potential for use as transdermal drug delivery vehicles
due to their thermodynamic stability and spontaneous formation (Shakeel et al.,
2008). The composition and internal structure of ME can affect the internal mobility
of the drugs in the vehicle, which influences the transdermal drug delivery
performance of ME (Kreilgaard, 2002). MCM are approved for human use and have
been incorporated into commercial formulations for decades (Paudel et al., 2010).
MCM are known transdermal permeation enhancers and can be easily incorporated
into ME formulations (Furuishi et al., 2007, Russell-Jones and Himes, 2011).
Furthermore, MCM have broad spectrum antimicrobial properties including antibiofilm activity (Schlievert et al., 1992, Bergsson et al., 2001, Hess et al., 2014,
Proctor, 2015a). Taken together, these properties of MCM make them highly
attractive for use in more effective, topical antimicrobial formulations.
The aim of this project was to utilize MCM in biocompatible ME formulations for
transdermal drug delivery. The influence of medium chain mono and triglyceride
concentration, non-ionic surfactants and co-surfactants on ME systems was
characterized through the construction of pseudo-ternary phase diagrams and the
transdermal permeation properties of selected formulations was assessed in vitro and
in vivo.
Present project demonstrated that formulation ME_A effectively enhanced the
transdermal delivery rate of NaFlu through full thickness mouse skin. Further
assessment revealed MCM act as the permeation enhancer in formulation ME_A
while the presence of GTCC in the formulation ME_A decreased the transdermal
permeation enhancing properties of MCM. When investigating the permeation
profiles of variable surfactants incorporated with MCM, Surfactant BRIJ O10
demonstrated synergistic effect on transdermal permeation delivery of NaFlu. It is
proved that increasing MCM can expand the AT at a ratio to GTCC of 1: 1.
Moreover, phase diagrams which established with MCM/EtOH and surfactants
produced larger monophasic area in comparison with that of MCM/GTCC based
formulations, suggesting EtOH is potent to form stable ME formulations. After
evaluating the effect of different surfactants on the transdermal delivery profiles,
permeation results presented that the NaFlu J s produced by formulation ME_T8 =
ME_BJ > ME_CO > ME_T2.
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Previous researches have shown that gentamicin acts synergistically with MCM to
eradicate on S. aureus biofilm (Proctor, 2015b, Hess et al., 2014). Therefore, the
incorporation of gentamicin into ME formulations was assessed. Results showed that
formulation ME_T8, ME_CO and ME_BJ all effectively enhanced the transdermal
delivery rate of gentamicin through full thickness mouse skin. ME_T8 was chosen to
test the bio-distribution in vivo. The bio-distribution results showed that gentamicin
accumulated in the kidney reaching statistical significance after application of
formulation ME_T8 (both single dose and double dose groups) in comparison with
the control group. This indicates that ME_T8 facilitated the transdermal delivery of
gentamicin through mouse skin to produce detectable systemic drug levels.
In conclusion, ME formulations composed by MCM and EtOH are favourable for the
transdermal drug delivery. In future studies, it is recommended that characterizing
ME formulations with conductivity measure, rheology test and polarization
microscopy would be promising. What’s more, it is promising to examine variable
antibiotic drugs incorporated with ME formulations.
Overall, this set of topical ME formulations with enhanced permeation capacity for
the antibiotics (gentamicin) were constructed and evaluated in mice body. Greater
range of ME formulations were found to use as transdermal delivery vehicles in this
article, indicating that optimized ME formulations have more potential to fulfil
variable requirement. The permeation enhancement ability of ME formulations
presented in this study, informing ME formulations have a great capacity to
incorporate with antibiotic drugs to replace current commercial antibiotic
cream/ointment/gel.
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7 APPENDIX
7.1

Materials and solutions

Phasphate buffered salin (PBS) (1 x)

NaCl

8 g/L

KCl

0.2 g/L

Na2HPO4

1.44 g/L

KH2PO4

0.24 g/L
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7.2

Specification Sheets

Appendix 7.1 Certificate of analysis of Crodamol GTCC-LQ-(SG), listing the
percentage breakdown of the oil components, indicating 57.8 caprylic and 42.2%
capric triglycerides
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Appendix 7.2 Certificate of analysis of Capmul MCM, listing the percentage
breakdown of the oil components, indicating 58.4% MCM, glyceryl monocaprylate
(C8) and glyceryl caprate (C10).
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7.3

Transdermal delivery assay of NaFlu (MCM/GTCC based formulations)

Accumulated NaFlu (ng/cm2)

PBS 16-04-2013
800
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Time post application (h)

24

Appendix 7.3 Cumulative transdermal delivery of NaFlu through mouse skin in vitro
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in
Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological
replicates.

Accumulated NaFlu (ng/cm2)

MCM only 22-05-2013
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Appendix 7.4 Cumulative transdermal delivery of NaFlu through mouse skin in vitro
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in
Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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Accumulated NaFlu (ng/cm2)

Tw/Sp only 01-10-2014
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Appendix 7.5 Cumulative transdermal delivery of NaFlu through mouse skin in vitro
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in
Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological
replicates.

Accumulated NaFlu (ng/cm2)

MCM_Tw80/Sp80_NaFlu 27-05-2013
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Appendix 7.6 Cumulative transdermal delivery of NaFlu through mouse skin in vitro
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in
Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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Accumulated NaFlu (ng/cm2)

GTCC_TS 05-10-2014
250
200
150
100
50
0

0

4

8

12

16

20

24

Time post application (h)

Appendix 7.7 Cumulative transdermal delivery of NaFlu through mouse skin in vitro
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in
Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological
replicates.

Accumulated NaFlu (ng/cm2)
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Appendix 7.8 Cumulative transdermal delivery of NaFlu through mouse skin in vitro
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in
Table 3.2. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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Accumulated NaFlu (ng/cm2)
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Appendix 7.9 Cumulative transdermal delivery of NaFlu through mouse skin in vitro
over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described in
Table 3.2. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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Appendix 7.10 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.1. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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Accumulated NaFlu (ng/cm2)

MCM_CO 15-07-2013
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Appendix 7.11 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.2. Each point represents means ± standard deviation of 3 to 4 biological
replicates.

Accumulated NaFlu (ng/cm2)

MCM_BJ 15-07-2013
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Appendix 7.12 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.2. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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Appendix 7.13 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.3. Each point represents means ± standard deviation of 3 to 4 biological
replicates.

Accumulated NaFlu (ng/cm2)

ME_C 21-10-2013
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Appendix 7.14 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.3. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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Accumulated NaFlu (ng/cm2)

ME_D 13-08-2013
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Appendix 7.15 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.3. Each point represents means ± standard deviation of 3 to 4 biological
replicates.

Accumulated NaFlu (ng/cm2)
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Appendix 7.16 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.3. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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Accumulated NaFlu (ng/cm2)

ME_F 29-07-2013
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Appendix 7.17 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.3. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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7.4

Transdermal delivery assay of NaFlu (MCM/EtOH based formulations)

Accumulated NaFlu (ng/cm2)

ME_BJ 08/10/2014
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Time post application (h)

Appendix 7.18 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.4. Each point represents means ± standard deviation of 3 to 4 biological
replicates.

Accumulated NaFlu (ng/cm2)

ME_CO 08/10/2014
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Appendix 7.19 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.4. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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Accumulated NaFlu (ng/cm2)

ME_T2 09/10/2014
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Time post application (h)

Appendix 7.20 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.4. Each point represents means ± standard deviation of 3 to 4 biological
replicates.

Accumulated NaFlu (ng/cm2)
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Appendix 7.21 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.4. Each point represents means ± standard deviation of 3 to 4 biological
replicates.
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Accumulated NaFlu (ng/cm2)

MCM/EtOH 10/10/2014
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Appendix 7.22 Cumulative transdermal delivery of NaFlu through mouse skin in
vitro over 24 hours. This formulation contained 1.2 mg/mL NaFlu and was described
in Table 3.4. Each point represents means ± standard deviation of 3 to 4 biological
replicates.

Gentamicin accumulated (ug/cm2)

7.5

Transdermal delivery assay of gentamicin (MCM/EtOH based
formulations)

PBS 19/02/2014
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Appendix 7.23 Cumulative transdermal delivery of gentamicin through mouse skin
in vitro over 24 hours. This formulation contained 20 mg/mL gentamicin that was
spiked with 0.5 µCi tritium labelled gentamicin and was described in Table 3.4. Each
point represents means ± standard deviation of 3 to 4 biological replicates.
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Gentamicin accumulated (ug/cm2)

ME_BJ 01/07/2014
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Time post application (h)

Appendix 7.24 Cumulative transdermal delivery of gentamicin through mouse skin
in vitro over 24 hours. This formulation contained 20 mg/mL gentamicin that was
spiked with 0.5 µCi tritium labelled gentamicin and was described in Table 3.4. Each

Gentamicin accumulated (ug/cm2)

point represents means ± standard deviation of 3 to 4 biological replicates.
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Appendix 7.25 Cumulative transdermal delivery of gentamicin through mouse skin
in vitro over 24 hours. This formulation contained 20 mg/mL gentamicin that was
spiked with 0.5 µCi tritium labelled gentamicin and was described in Table 3.4. Each
point represents means ± standard deviation of 3 to 4 biological replicates.
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Gentamicin accumulated (ug/cm2)
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Appendix 7.26 Cumulative transdermal delivery of gentamicin through mouse skin
in vitro over 24 hours. This formulation contained 20 mg/mL gentamicin that was
spiked with 0.5 µCi tritium labelled gentamicin and was described in Table 3.4. Each
point represents means ± standard deviation of 3 to 4 biological replicates.
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Gentamicin accumulated in the spleen (ug/g of tissue)

7.6

Bio-distribution assay of gentamicin (MCM/EtOH based formulations)

2.0
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Appendix 7.27 Cumulative gentamicin amount in the spleen of mice in vivo over 48
hours. All formulations contained 10 mg/mL gentamicin that was spiked with 0.5
µCi tritium labelled gentamicin and are described in Table 3.4. Each point represents
means ± standard error of the mean (SEM) of 3 to 4 biological replicates. At 24 h,
the amount of gentamicin in spleen was significantly lower after ME treatment when

Gentamicin accumulated in the liver (ug/g of tissue)

compared to the PBS treatment (indicated with *, p < 0.05).
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Appendix 7.28 Cumulative gentamicin amount in the liver of mice in vivo over 48
hours. All formulations contained 10 mg/mL gentamicin that was spiked with 0.5
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µCi of tritium labelled gentamicin and are described in Table 3.4. Each point
represents means ± standard error of the mean (SEM) of 3 to 4 biological replicates.
At 12 h and 48 h, the amount of gentamicin in liver was significantly lower after ME

Gentamicin accumulated in the lung (ug/g of tissue)

treatment when compared to the MEx2 treatment (indicated with *, p < 0.05).
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Appendix 7.29 Cumulative gentamicin amount in the lung of mice in vivo over 48
hours. All formulations contained 10 mg/mL gentamicin that was spiked with 0.5
µCi of tritium labelled gentamicin and are described in Table 3.4. Each point
represents means ± standard error of the mean (SEM) of 3 to 4 biological replicates.
At 3 h, 6 h, 12 h and 24 h, the amount of gentamicin in lung was significantly lower
after ME treatment when compared to the MEx2 treatment (indicated with *, p <
0.05).
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Gentamicin accumulated in the small intestine (ug/g)
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Appendix 7.30 Cumulative gentamicin amount in the small intestine of mice in vivo
over 48 hours. All formulations contained 10 mg/mL gentamicin that was spiked
with 0.5 µCi tritium labelled gentamicin and are described in Table 3.4. There is no
significant different between each treatment group. Each point represents means ±

Gentamicin accumulated in the muscle (ug/g of tissue)

standard error of the mean (SEM) of 3 to 4 biological replicates.
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Appendix 7.31 The transdermal permeation gentamicin amount accumulated in the
underneath muscle at the site of topical application of mice in vivo over 48 hours. All
formulations contained 10 mg/mL gentamicin that was spiked with specific amount
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of tritium labelled gentamicin and are described in Table 3.4. Each point represents
means ± standard error of the mean (SEM) of 3 to 4 biological replicates. At 6 h, the
amount of gentamicin in the muscle was significantly lower after ME treatment when
compared to the PBS and MEx2 treatment (indicated with *, p < 0.05). At 24 h, the
amount of gentamicin in the muscle was significantly lower after ME treatment than
that after PBS treatment group (indicated with **, p < 0.05). The gentamicin
amounts in the muscle after both ME treatment and MEx2 treatment were

Gentamicin accumulated in the lymph nodes (ug/g of tissue)

significantly lower than the PBS treatment in the 48 h (indicated with ***, p < 0.05).
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Appendix 7.32 Cumulative gentamicin amount in the lymph nodes of mice in vivo
over 48 hours. All formulations contained 10 mg/mL gentamicin that was spiked
with 0.5 µCi of tritium labelled gentamicin and are described in Table 3.4. Each
point represents means ± standard error of the mean (SEM) of 3 to 4 biological
replicates. At 6 h, the amount of gentamicin in the lymph nodes was significantly
lower after ME treatment when compared to the PBS treatment (indicated with *, p <
0.05).

80

